Increasing Prevalence of Cancers, and Other Chronic Diseases to Fuel the Growth of Neoantigens Market
Cancer has surpassed heart disease as the leading cause of death worldwide. According to the World Health Organization, cancer was the leading cause of death among individuals under the age of 70 in 183 countries and the fourth leading cause of death in 123 nations in 2020. According to the International Agency for Research on Cancer (IARC), the number of new cancer diagnoses globally is anticipated to reach 27.5 million by 2040, with 163 million deaths due to the disease. In the coming years, lifestyle changes, insufficient physical activity, smoking, and unpredictably changing health and climatic conditions are all expected to contribute to a rise in global cancer incidence. The increased prevalence of cancer has put pressure on healthcare systems all around the world. It has thus become imperative to keep track of and prevent the rising number of cancers around the world through improved cancer treatment and prevention. This is likely to offer a push to neoantigens market in the near future.
The World Health Assembly, for example, enacted Resolution Cancer (WHA70.12) in 2017, which calls for an integrated approach to cancer prevention, and control. The WHO and other countries have been urged to increase their efforts to meet the targets set forth in the Global Action Plan (2013-2020) for the prevention and management of non-communicable diseases (NCDs) and the 2030 UN Agenda for Sustainable Development to reduce cancer-related early mortality. Furthermore, several private organisations have embraced the action plans to tackle the rising cancer burden, creating a desire for more effective cancer preventive methods. As the incidence of cancer rises, there will be a growing demand for new and effective therapeutic strategies, which will drive the worldwide neoantigens market.
Neoantigen, also called tumour-specific antigen (TSA), is a repertoire of peptides that arise as the result of DNA mutations in tumour cells. Unlike the other two common types of tumour antigens, viz. tumour-associated antigens (TAAs), and cancer-germline antigens (CGAs), tumour neoantigen is the truly foreign protein and entirely absent from normal human organs or tissues. As a result, targeting neoantigens could allow the patient’s immune system to exclusively find and attack cancer cells without harming normal healthy cells. Decades of work has increasingly shown their potential for cancer immunotherapy.
Increasing Clinical Trials in Combination Therapy to Drive Growth of Neoantigens Market
Combination therapy is expected to be the fastest-growing segment of the neoantigens market over the forecast period. Due to the expanding number of clinical trials for neoantigens combined with immune checkpoint inhibitors (ICIs), or other cancer medicines, the market for combination therapy is likely to grow in the future years. Most firms have begun clinical studies for neoantigens as part of combination therapy. Gritstone Oncology, Inc., for example, has started the SLATE and GRANITE phase 1/2 clinical studies using their heterologous prime-boost system in combination with checkpoint inhibitor therapy. Gritstone Oncology, Inc. has also partnered with Bristol-Myers Squibb Company to conduct the clinical research, which will assess the safety and tolerability of SLATE and GRANITE in combination with OPDIVO (nivolumab) and OPDIVO with YERVOY (ipilimumab) in patients with solid tumours.
Increased in Clinical Studies along with Breakthroughs in Cancer Therapies to Drive Growth of North America Neoantigens Market
North America is the largest user of neoantigens and is expected to grow at the fastest rate throughout the forecast period. The United States, followed by Canada, and Mexico, is the largest market for neoantigens. The market is rising due to an increase in the number of clinical studies, breakthroughs in cancer immunotherapies, and increased funding from governments in different countries. Furthermore, the drastically rising cancer incidences in all North American countries are expected to provide potential possibilities for the market throughout the forecast period. In the North American region, the United States is anticipated to be the largest neoantigens market. The market here is developing due to an increase in clinical trials, increased spending in neoantigen research and development, and increased cooperation between firms.
With the rising number of cancer patients in the region and the growing desire for sophisticated treatment strategies, North America is expected to dominate the neoantigen market. Immunotherapy's acceptance has grown because of biotechnology advancements, propelling its application in customised treatment even further. Immunotherapy is commonly used to treat cancer, and some immunotherapy treatments include neoantigens, which are antigens found on the surface of cancer cells. As a result, neoantigens are being explored extensively in cancer treatment, thereby boosting the expansion of neoantigens market. Researchers can use neoantigens to identify patients' immune systems and uncover antigens to target cancer cells without upsetting healthy cells because of their uniqueness.
The dramatically increased incidences of cancer are adding to the market's rise. The rising number of cancer cases has put a strain on healthcare systems. As a result, both public and private players have launched several projects to address the rising cancer rates. Clinical trials for neoantigens are being supported by government and private agencies to implement preventive and control measures. The FDA's oncology team, for example, receives funding from the OCE Scientific Collaborative to participate in regulatory science research, including internal research initiatives and collaborations with external specialists, according to an FDA post from November 2020.
Global Neoantigens Market: Competitive Landscape
In January 2021, Genocea announced the publishing of cancer discovery. The advantages of using the ATLAS platform for neoantigen detection. This finding enhances neoantigen immunotherapies by ensuring that the right neoantigens are targeted while Inhibigens are removed. On the other hand, in November 2020, Cellesce Ltd. has teamed up with Manchester BIOGEL to produce totally synthetic animal-free three-dimensional (3D) scaffolds that simulate the physiological milieu in the human body, allowing for the fabrication, scale-up, and improved reproducibility of patient-derived organoids.
Few of the players in the neoantigens market include Achilles Therapeutics plc,Cellesce ltd, Frame Cancer Therapeutics, Genocea, Gradalis, Inc., Medigene AG, Immunicum AB, Ziopharm Oncology, Inc, Gritstone Oncology, Moderna, Inc, and Advaxis, Inc.
Regional Classification of the Global Neoantigens Market is Described Below:
Middle East and Africa
*Regions and countries are subject to change based on data availability
Key Elements Included In The Study: Global Neoantigens Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.Read more